Impact of rotavirus vaccination on hospitalizations for rotavirus diarrhea: The IVANHOE study

Impact of Rotavirus Vaccine on Premature Infants

“…After introduction of the vaccination program, we report a 2.6-fold (95% CI, 1.3 to 5.2) and an 11-fold (95% CI, 3.5 to 34.8) decrease in the number of hospitalizations for rotavirus in this population in the two epidemic seasons following the vaccine introduction and in the third season. This impact was greater than the impact shown in the IVANHOE study for infants younger than 2 years of age, whose number of hospitalizations was divided by a factor of 2 (95% CI, 1.6 to 2.7) during the second epidemic season following vaccine introduction (14). The results of the IVANHOE study were in line with those obtained from observational studies implemented in developed countries after the introduction of routine immunization (10-13, 20, 21), where a decrease was found in cases of rotavirus diarrhea in the year following the introduction of routine vaccination.…”

“…gov under registration no. NCT00740935) (14) confirmed these observations by showing a 2-fold decrease (95% CI, 1.6 to 2.7) in hospitalization rates for rotavirus diarrhea in infants under 2 years old with vaccine coverage of 47.1%. Since then, the effectiveness of RotaTeq has been observed in several developed countries (15)(16)(17).…”

Efficacy of the pentavalent rotavirus vaccine, RotaTeq® (RV5), between doses of a 3-dose series and with less than 3 doses (incomplete regimen)

“…These significant reductions have been observed in other postlicensure disease surveillance and effectiveness studies in the US [12][13][14] and other countries that have introduced RV5 into their childhood immunization schedules. [14][15][16][17][18][19] Conclusions. RV5 is a 3-dose vaccine that protects infants against RVGE.…”

Evaluation of the Cost-Effectiveness of Vaccination of Children with 5-valent Vaccine against Rotavirus Infection in the Russian Federation

“…В то же время во Франции при охвате вакцинацией равном 47% снижения заболеваемости РВИ у детей старше 2 лет выявлено не было [27]. Это демонстрирует необходимость организационных мер по обеспечению максимального охвата вакцинацией для развития попу-ляционного эффекта.…”